- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03795870
Enteral Nutrition Tolerance and the Gut Microbiome Study
The Effect of Blenderized Tube Feeding on Enteral Nutrition Tolerance and the Gut Microbiome: A Pilot Study
The current study will enroll patients who are going to require enteral nutrition support for at least 4 weeks and randomize them to standard polymeric formulas or blenderized tube feeding. They will be asked to fill out a questionnaire about their tolerance of enteral feeds. They will also be asked to provide stool samples before enrollment and after 4-6 weeks.
The study is trying to assess whether the use of whole food in blenderized tube feeding will be better tolerated and also lead to greater diversity of microbiome.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Malnutrition remains highly prevalent in both acute and chronic diseases, leading to longer hospital length of stay, greater risk of hospital readmission, and overall increase in morbidity and mortality. Over the last few decades, studies have continued to reveal significant clinical benefit from nutrition support, including reduction in complications and length of stay, maintenance of gastrointestinal integrity, and overall improvement in clinical outcomes and mortality. Despite high prevalence of Home Enteral Nutrition(HEN), patients continue to struggle with intolerance of tube feeds leading to chronic underfeeding and weight loss. Current guidelines recommend using standard polymeric formula or high-protein standard formula in the hospitalized patient requiring EN and also recommend against routine use of formulas designed to be immune-modulatory, elemental/semi-elemental, disease-specific (diabetes), and organ-specific (hepatic, renal, pulmonary).
Blenderized Tube Feeding(BTF) offers a number of advantages to standard polymeric formula including being able to modify the macro-nutrient and fiber content based on patient preference. BTF use has also been increasing significantly in the past few years.
The gut microbiome, or gut host environment, consists of approximately 10 thousand cells and has been the subject of much interest as it relates to gastrointestinal homeostasis. Our aim therefore is to (1) characterize the structure and dynamics of complex microbial communities using 16S rRNA- encoding gene sequences; (2) determine how they change with EN and; (3) how they may be correlated with tolerance of EN.
A total of fifty subjects who are willing to participate in current trial and who meet eligibility will be recruited from the Mayo Clinic HEN program. Suitable subjects will be identified when they present at the initial HEN visit prior to undergoing enteral tube placement.
Written informed consent will be obtained from all individuals who participate in the study. The principal investigator or member of study team meet with each participant, review the consent form in detail and confirm the subject's understanding of the study. The study team will answer all questions posed by the participants and when convinced that the subject verbally demonstrates understanding of the protocol, they will obtain a signed consent. Only designated staff members are authorized to obtain informed consent.
At the pre-enteral tube visit, subjects will complete a gastrointestinal quality of life (QoL) questionnaire which will form the baseline assessment for symptoms and functional status. Body composition will be measured using Bio-impedance analysis (BIA; InBody™). A stool specimen will be obtained for analysis of the gut microbiome at baseline. Baseline clinical data such as current medical problems will be recorded.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic in Rochester
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- All subjects who are above 18 years of age, who present to Mayo Clinic HEN program for initial evaluation prior to enteral tube placement
- Require enteral nutrition support for at least 4-6 weeks from enrollment
Exclusion Criteria:
- Patients with type 1 or 2 diabetes will be excluded due to the known pre-existing changes in the gut microbiome in this population.
- Patients who have had exposure to probiotics, prebiotics or antibiotics in the preceding 4 weeks will be excluded.
- Known allergy or intolerance to study products will be excluded.
- Patients on parenteral nutrition will be excluded.
- If oral feeding accounts for >25% of daily caloric intake.
- Presence of entero-cutaneous fistula
- Patients with short bowel syndrome will be excluded.
- Patients who have had bariatric surgery or other alteration of GI tract will be excluded.
- Hematologic malignancy with absolute neutrophil count < 500/mm3
- History of renal or liver transplant or on transplant list.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Polymeric Tube Feeds
This arm will be receiving Polymeric Tube Feeds as a part of the regular HEN Protocol.
|
Polymeric tube feeds will be given to HEN patients to assess the percentage of goal calories provided in comparison with blenderized tube feeds
|
|
Active Comparator: Blenderized Tube Feeds
This arm will be receiving Blenderized tube feeds as a part of the regular HEN Protocol.
|
Blenderized tube feeds will be given to HEN patients to assess the percentage of goal calories provided in comparison with polymeric tube feeds
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Percentage of goal calories provided
Time Frame: 4-6 weeks
|
4-6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Gut microbiome
Time Frame: 1 week, 4-6 weeks
|
A stool specimen will be collected to assess the composition of the gut microbiome at baseline and at the follow-up visit.
|
1 week, 4-6 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Manpreet S Mundi, MD, Mayo Clinic
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 18-004416
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Enteral Feeding Intolerance
-
Centre Hospitalier Saint Joseph Saint Luc de LyonRecruitingEnteral Feeding IntoleranceFrance
-
Sohag UniversityRecruitingEnteral Feeding IntoleranceEgypt
-
Brno University HospitalRecruitingEnteral Feeding IntoleranceCzechia
-
The University of Texas Health Science Center at...Avanos MedicalCompleted
-
Brno University HospitalMasaryk UniversityRecruiting
-
Boston Children's HospitalRecruitingEnteral Feeding IntoleranceUnited States
-
Ain Shams UniversityFuture University in EgyptCompletedEnteral Feeding IntoleranceEgypt
-
NestléCompletedEnteral Feeding IntoleranceCanada
-
Lyric PharmaceuticalsCompletedEnteral Feeding Intolerance (EFI)United States, Spain, Netherlands
-
Hospices Civils de LyonCompletedMechanical Ventilation Complication | Enteral Feeding IntoleranceFrance
Clinical Trials on Polymeric Tube Feeds
-
Hartford HospitalSpero TherapeuticsCompleted
-
Carilion ClinicVirginia Polytechnic Institute and State UniversityRecruitingCritical Illness | Malnutrition | Trauma | Surgery | Gastrostomy | Mechanical Ventilation | Procedural SequelaeUnited States
-
University of MichiganChildren's Mercy Hospital Kansas CityTerminatedEnteral Nutrition | Enteral Feeding | Gastrostomy TubeUnited States
-
University of Illinois at ChicagoCompletedHead and Neck CancerUnited States
-
Boston Children's HospitalBeth Israel Deaconess Medical CenterNot yet recruitingBronchopulmonary DysplasiaUnited States
-
Rajeev KumarRecruitingFeeding Patterns | Ventilator Lung; Newborn | Prematurity; ExtremeUnited States
-
State University of New York at BuffaloRecruitingCritical Illness | Nutritional Deficiency | Tracheostomy ComplicationUnited States
-
Boston Children's HospitalNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RecruitingOropharyngeal Dysphagia | Brief Resolved Unexplained Event | Apparent Life Threatening EventUnited States
-
Indiana UniversityCompletedPostoperative Feeding Following PyloromyotomyUnited States
-
Hospital General "Dr. Miguel Silva" de MoreliaCompletedCritical Illness | Enteral Nutrition Therapy | TBI Traumatic Brain InjuryMexico